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Abstract
Developing antiviral drugs, vaccines and diagnostic markers is still the most ambitious challenge in clinical virology. In the past few dec-
ades, data from high-throughput technologies have allowed for the rapid development of new antiviral therapeutic strategies, thus mak-
ing a profound impact on translational research. Most of the current preclinical studies in virology are aimed at evaluating the dynamic
composition and localization of the protein platforms involved in various host–virus interactions. Among the different possible
approaches, mass spectrometry-based proteomics is increasingly being used to deﬁne the protein composition in subcellular compart-
ments, quantify differential protein expression among samples, characterize protein complexes, and analyse protein post-translational
modiﬁcations. Here, we review the current knowledge of the most useful proteomic approaches in the study of viral persistence and
pathogenicity, with a particular focus on recent advances in hepatitis C research.
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Introduction
Our understanding of host–virus interaction has recently
been advanced by system-wide analyses. ‘Omics’ technologies
such as genomics and transcriptomics have greatly enhanced
the systemic evaluation of gene expression. Despite their
usefulness, genomics and transcriptomics approaches have
certain limitations. First, gene mutations and mRNA expres-
sion levels determined quantitatively often do not mirror the
real situation in terms of mature proteins. Moreover, transla-
tional and post-translational regulation affect not only the
level of a mature protein but also its function. In fact, the
effects on protein structure and biological function of alter-
native splicing, post-translational modiﬁcations and virus–host
interactions cannot be easily predicted by genomics and
transcriptomics studies. In light of this, mass spectrometry
(MS)-based proteomics is a unique and necessary tool for
system-wide, structural and functional analysis of the effec-
tors of biological functions.
MS-based Proteomics
Proteomics offers a great variety of applications. Each experi-
mental proteomic analysis can be summarized in three major
steps: (i) sample preparation; (ii) protein separation; and (iii)
identiﬁcation. A downstream bioinformatic analysis can also
be performed for data processing (Fig. 1).
(i) The ﬁrst requirement for successful proteomic analysis is
appropriate and speciﬁc protein sample enrichment by frac-
tionation techniques. Indeed, many of the crucial viral life-cycle
steps are associated with deﬁned subcellular complexes;
moreover, the more attractive therapeutic targets or prognos-
tic markers are either speciﬁc cell membrane components, or
circulate in biological ﬂuids at low concentrations [1,2].
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(ii) The sample preparation step leads to a complex mix-
ture of different proteins. Proper separation of these mix-
tures is essential for the accurate identiﬁcation and
quantiﬁcation of proteins by MS. Traditionally, two-dimen-
sional gel electrophoresis (2-DE) has been considered to be
a suitable protein separation method. In the past few years,
this technique has been complemented by a quantitative
application (two-dimensional difference in-gel electrophoresis
(DIGE)) that allows for analysis of the relative changes in
protein abundance among different samples [3]. However,
owing to recent technical advances, high-resolution nano-
liquid chromatography is gradually replacing both 2-DE and
DIGE. This is because the low volume and low ﬂow rate of
nano-liquid chromatography allows for analysis of proteins
on an attomole level, signiﬁcantly reducing solvent waste and
enhancing MS-based protein identiﬁcation [4].
(iii) MS is the core of proteomics. The biological applica-
tions of MS have grown exponentially since the discovery of
matrix-assisted laser desorption ionization and electrospray
ionization techniques [5]. Protein identiﬁcation is the primary
aim of MS in proteomic applications. Because of the difﬁcul-
ties in analysing the mass of entire proteins, identiﬁcation is
performed on peptides obtained from them by proteolytic
cleavage.
The development of quantitative techniques has extended
MS applications in proteomics. In fact, high-throughput rela-
tive and absolute protein abundance measurements are now
possible in liquid chromatography/MS conﬁgurations with a
variety of isotope-mediated approaches, such as isotope-
coded afﬁnity tags, isotope-coded protein labelling, the accu-
rate mass and time tag approach, isobaric tags for relative
and absolute quantitation, and stable isotope labelling of
amino acids in cell culture [6].
Proteomic Applications in Preclinical and
Clinical Virology
Viral replication and propagation cause host cellular proteome
variations. The identiﬁcation of proteins whose presence is
affected by the presence of a virus may serve for either diag-
nostic or prognostic purposes, or for the discovery of novel
therapeutic targets (Fig. 2). Biomarker investigations are nor-
mally performed on biological ﬂuids such as serum, plasma,
and saliva. An excellent example of this can be observed in an
investigation by Wiederin et al. [7] on sera of human immuno-
deﬁciency virus-1-associated dementia patients that allowed
for identiﬁcation of two differentially expressed proteins (pre-
albumin and gelsolin) as early biomarkers in human immunode-
ﬁciency virus-induced neurodegenerative disorders.
Interestingly, biomarker identiﬁcation can also be obtained
with tissues or cell cultures as a protein source. For
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FIG. 1. MS-based proteomic workﬂow.
Experimental proteomic analysis consists of
several steps, listed in the different panels:
sample preparation (i), protein or peptide mix-
ture separation (ii), protein identiﬁcation by
MS (iii), and bioinformatic analysis (iv). 2-DE,
two-dimensional gel electrophoresis.
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example, by analysing the hepatitis B virus-replicating hepa-
toma HepG2 cell line with an iTRAQ approach, Feng et al.
[8] identiﬁed apolipoprotein (Apo)A-I and a2-HS glycopro-
tein as prognostic biomarker candidates for hepatitis B virus-
associated hepatocellular carcinoma (HCC).
The efﬁcacy of antiviral agents often depends on their ability
to reach viral subcellular niches in the host cell. Differential pro-
teomics has also proved to be a suitable tool for the subcellular
localization of viruses. Emmott et al. [9] used this approach in
the study of coronavirus infectious bronchitis virus infection. In
particular, a SILAC-based proteomic analysis allowed for identi-
ﬁcation of the viral protein N localized in the nucleolus, thus
opening new avenues for the development of compounds tar-
geted to the infectious bronchitis virus life cycle.
The potential of MS-based proteomics is well established
in functional and structural studies [10]. The complete
description of viral proteins forming the infectious particles
and the characterization of the virus–host protein interac-
tions are current challenges in molecular virology with great
implications for translational and clinical research.
Approaches for protein–protein interaction analysis, such as
tandem afﬁnity puriﬁcation and co-immunoprecipitation, cou-
pled with MS-based proteomics have elucidated several
mechanisms by which viruses exploit host molecular machin-
eries for their beneﬁt, as well as the host countermeasures
(Fig. 2). Notably, in one of these proteomic studies, very
low-density lipoprotein-associated proteins were identiﬁed
during hepatitis C virus (HCV) replication complex puriﬁca-
tion [11], thus revealing that assembly and secretion of very
low-density lipoprotein particles are required for virus pro-
duction and propagation.
Proteomic Applications to Hepatitis C
Up to 200 million persons worldwide are infected with
HCV; this infection causes chronic liver disease, eventually
leading to cirrhosis and HCC [12].
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FIG. 2. Proteomic applications in virology research. Differential proteomics allows comparison of the abundance proﬁles of proteins isolated
from different protein sources (left workﬂow). Structural and functional proteomics are performed to analyse viral-induced protein–protein
interaction and post-translational modiﬁcations (PTMs) (right workﬂow). Speciﬁc bites: speciﬁc bound proteins; Vs: versus.
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The current standard therapy for chronic hepatitis C is
the combination of peginterferon and ribavirin, which results
in a sustained virological response (SVR) in only half of the
patients [13].
This therapy, besides being relatively inefﬁcient, is also
often associated with serious side effects. Novel direct-acting
antiviral treatments, which target viral proteins, have recently
been introduced, and should allow an increased SVR rate to
be achieved; however, their efﬁcacy still depends on their
combination with peginterferon and ribavirin. Therefore, it is
crucial to identify both pretreatment and early treatment
outcome predictors, in order to provide consistent estimates
of the SVR. Moreover, although these drugs represent a
major step towards HCV eradication, they have the limita-
tion of selecting for drug-resistant viruses [14]. For this rea-
son, identiﬁcation of novel drugs that target host factors
necessary for the virus life cycle remains an important goal
in the near future to halt HCV infection.
The progress in proteomics has led to improvements in
the ﬁeld of molecular mechanisms of HCV-induced patho-
genesis and the identiﬁcation of markers valuable for: (i) dis-
criminating between patients who respond (SVR) and do not
respond to the current antiviral therapy; and (ii) for ﬁbrosis,
cirrhosis or HCC diagnosis. In this section, we provide a few
examples of these recent ﬁndings.
Recently, when comparing the circulating lipoprotein pro-
teomes of HCV-infected patients and healthy donors, we
observed that HCV induces impaired association of ApoA-I
with the low-density lipoprotein particles [15]. Using HCV
cellular models, we demonstrated that ApoA-I–low-density
lipoprotein association impairment occurs during lipoprotein
generation, and is caused by viral replication. Interestingly,
ApoA-I downregulation induces signiﬁcant impairment of
HCV production [15], thus reinforcing the notion that HCV
requires the host lipoprotein machineries [11].
To understand the molecular mechanism of HCV-induced
lipoprotein generation defects, we performed quantitative prote-
omics analysis of SILAC-labelled ApoB-100-containing subcellular
fractions. We demonstrated, in vitro, that HCV induces ferritin
heavy chain (Fth) upregulation, and that Fth is the cellular deter-
minant for HCV-induced ApoB-100 secretion inhibition. Impor-
tantly, a negative correlation between ferritin and ApoB-100
serum levels was found in patients. Moreover, Fth expression
was found to be required for robust HCV infection. Altogether,
our results provide a novel molecular explanation for HCV-
induced hypobetalipoproteinaemia and liver steatosis, which
could be useful for developing a new antiviral strategy [16].
These data, together with other results not mentioned
here, underline how HCV–lipoprotein interactions represent
attractive targets for indirect-acting antiviral development.
Elegant studies performed by Katze’s laboratory shed light
on the early steps of HCV pathogenesis. By means of an
Accurate Mass and Time tag (AMT) approach, they analysed
the proteome of sequential liver biopsy specimens of HCV-
infected patients (before, and 6 and/or 12 months after, liver
transplantation).
They generated a proteomic database of the highly per-
missive Huh-7.5 cells containing a full-length HCV replicon,
which allowed for the identiﬁcation of many proteins from
only 1 lg of the total liver biopsy extracts. Using liver biopsy
specimens from patients with different grades of ﬁbrosis, the
authors identiﬁed a subset of proteins that are able to indi-
cate whether a patient will progress to severe liver disease
post-transplantation. These included proteins involved in: (i)
amino acid, carbohydrate and lipid metabolism pathways
[17]; (ii) immune response (i.e. proinﬂammatory; acute-phase
response; cellular recruitment); and (iii) hepatoprotective
(i.e. associated with superoxide, cysteine, glutathione and
xenobiotic metabolism) and ﬁbrogenic (i.e. linked to epithe-
lial-to-mesenchymal transition) processes [18]. The observed
an increase in proinﬂammatory activity and an impairment in
antioxidant defence, suggesting that patients who develop sig-
niﬁcant liver injury experience elevated oxidative stress.
Importantly, these data were conﬁrmed by serum metabolo-
mics of an independent cohort of HCV patients [18].
Overall, these ﬁndings demonstrate the importance of using
in vitro observation for assisting the identiﬁcation of proteins/
pathways involved in HCV-induced liver disease progression.
Proteomics, together with other ‘omics’ approaches, has
been largely applied to identify prognostic markers of anti-
HCV therapy outcome. The main breakthroughs of genomic
and trascriptomic studies were the identiﬁcation of: (i) a sin-
gle-nucleotide polymorphism in the IL28B gene (coding for
interferon (IFN)-k3) [19]; and (ii) the dysregulation of liver
expression levels of IFN-inducible genes [20].
In this regard, we recently performed a proteomic analysis
of pretreatment liver biopsy specimens from patients with
SVRs and non-responding patients by 2D-DIGE/MS [21]. Our
study conﬁrmed the presence of an inverse correlation
between the levels of IFN-related genes and the rate of the
SVR, and also identiﬁed proteins involved in stress response
and energy metabolism as putative prognostic factors.
Proteomic studies from our and other laboratories have
also shown that post-translational modiﬁcations are another
source of prognostic markers of treatment outcome, such as
the charge modiﬁcation of dihydroxyacetone kinase, a negative
regulator of the MDA5-mediated antiviral pathway, detected
in liver biopsy specimens, and the phosphorylation of AKT,
JAK1, p70 S6 kinase, protein kinase C-f/k, TYK2 and ZAP-70
observed in peripheral blood mononuclear cells [21,22].
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Many efforts to identify prognostic and diagnostic markers
have been made with serum, as it is an easily accessible bio-
logical ﬂuid that may reﬂect immunological and pathological
events during chronic HCV infection. Despite these advanta-
ges, there are some drawbacks, of which the difﬁculty in
ﬁnding low-abundance proteins, owing to the presence of
high-abundance proteins (albumin, immunoglobulin, etc.), is
one of the most challenging. Many efforts have been also
made to overcome this problem.
In this regard, SELDI-TOF, a technology that combines
chromatography separation and MS analysis, has repre-
sented an important advance in identifying blood-circulating
markers. For instance, different pretreatment serum pro-
teins, whose levels signiﬁcantly differ between patients with
SVR and non-responding patients, were identiﬁed with this
approach [23]. Importantly, the association of serum pro-
tein levels with clinical and biochemical characteristics, such
as the stage of ﬁbrosis, IL28B polymorphisms, and viral
genotype, has led to a more accurate prediction of treat-
ment response, indicating that the combinatory analysis of
clinical and molecular data is required to achieve a reliable
prognostic test [23,24].
Moreover, Gangadharan et al. [25,26] identiﬁed low-abun-
dance plasma proteins (narrowing the pH range of 2-DE-
based proteomic analyses) of HCV patients with different
degree of liver ﬁbrosis. Among new candidate biomarkers,
the levels of six proteins (lipid transfer inhibitor protein,
complement C3d, complement C4, corticosteroid-binding
globulin, ApoJ, and ApoL1) were found to decrease inversely
with the patient’s ﬁbrosis grade [25,26].
In Beretta’s laboratory, extensive MS analysis of a large
cohort of HCC patients was performed after immunodeple-
tion of the most abundant plasma proteins and multidimen-
sional protein separation by 2D-HPLC, followed by SDS-
PAGE [27]. They found that osteopontin is a sensitive HCC
prognostic marker [27].
A further approach to identify HCV-related HCC biomar-
kers has been attempted by Nomura’s laboratory [28].
Downstream of a proteomics analysis on liver biopsy speci-
mens of HCC patients, the authors investigated the possibil-
ity of detecting serum autoantibodies directed against the
proteins found to be overexpressed. On the basis of their
ﬁndings with this approach, they propose the serum level of
anti-Ku86 antibodies as a potential biomarker for early
detection of HCC in HCV-infected patients [28].
Altogether, these studies provide initial evidence that the
recent development of reliable proteomic approaches may
(in the near future) allow for complete characterization of
HCV patient dysfunctions, in order to prevent and monitor
disease progression, and achieve virus eradication.
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